Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL3710793 | 0.97 | LMNA (0.65) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL826558 | 0.95 | LMNA (0.62) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL547729 | 0.95 | LMNA (0.62) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Silver SCHEMBL18889837 | 0.93 | LMNA (0.58) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL9142009 | 0.92 | LMNA (0.59) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL9360101 | 0.92 | LMNA (0.56) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL9142871 | 0.90 | PDE4A (0.59) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL9356215 | 0.90 | PDE4A (0.59) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Potassium Ion SCHEMBL30209157 | 0.90 | PDE4A (0.59) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL3389955 | 0.86 | LMNA (0.59) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150239-A1 | AQUEOUS-MISCIBLE OR AQUEOUS-DISPERSIBLE, VOC-FREE BIOCIDAL COMPOSITIONS FOR THE ENHANCED INHIBITION OF GRAM-NEGATIVE BACTERIAL STRAINS, AND METHOD OF PREPARING THE SAME | TROY TECHNOLOGY II, INC. | 2013-06-13 | — | — | US | disclosed |
| EP-2531034-A1 | AQUEOUS-MISCIBLE OR AQUEOUS-DISPERSIBLE, VOC-FREE BIOCIDAL COMPOSITIONS FOR THE ENHANCED INHIBITION OF GRAM-NEGATIVE BACTERIAL STRAINS, AND METHOD OF PREPARING THE SAME | ISP INVESTMENT INC. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011085067-A1 | AQUEOUS-MISCIBLE OR AQUEOUS-DISPERSIBLE, VOC-FREE BIOCIDAL COMPOSITIONS FOR THE ENHANCED INHIBITION OF GRAM-NEGATIVE BACTERIAL STRAINS, AND METHOD OF PREPARING THE SAME | ISP INVESTMENT INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150239-A1 | AQUEOUS-MISCIBLE OR AQUEOUS-DISPERSIBLE, VOC-FREE BIOCIDAL COMPOSITIONS FOR THE ENHANCED INHIBITION OF GRAM-NEGATIVE BACTERIAL STRAINS, AND METHOD OF PREPARING THE SAME | TMBIM6, BAX, DBI | LMNA 2091/4885PDE4A 3164/4885USP2 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.